This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Currently amended) A compound of formula I:



(I)

wherein:

R_1 is~~: a)~~ the moiety:



;

R_4 is hydrogen, halogen, C_1-C_3 alkyl, C_1-C_3 haloalkyl, C_1-C_3 perfluoroalkyl, C_1-C_3 alkoxy, C_1-C_3 perfluoroalkoxy, C_1-C_3 alkylthio, C_1-C_3 perfluoroalkylthio, $-OCHF_2$, -CN, -COOH, $-CH_2CO_2H$, $-C(O)CH_3$, $-CO_2R_7$, $-C(O)NH_2$, $-S(O)_2CH_3$, -OH, $-NH_2$, or $-NO_2$;

X is O;

R_5 is C_1-C_8 alkyl, C_1-C_3 perfluoroalkyl, C_3-C_6 cycloalkyl, $-CH_2$-C_3-C_6 cycloalkyl, heteroaryl, $-CH_2$-heteroaryl, phenyl, or arylalkyl where the alkyl chain is C_1-C_8, wherein the rings of the cycloalkyl, heteroaryl, phenyl, and aryl groups are optionally substituted by from 1 to 5 groups selected from halogen, C_1-C_3 alkyl, C_1-C_3 haloalkyl, C_1-C_3 perfluoroalkyl, C_1-C_3 alkoxy, C_1-C_3 perfluoroalkoxy, C_1-C_3 alkylthio, C_1-C_3 perfluoroalkylthio, $-OCHF_2$, -CN, -COOH, $-CH_2CO_2H$, $-C(O)CH_3$, $-CO_2R_7$, $-C(O)NH_2$, $-S(O)_2CH_3$, -OH, $-NH_2$, or $-NO_2$;

R_2 is hydrogen, C_1-C_6 alkyl, -CH_2-C_3-C_6 cycloalkyl, or C_1-C_3 perfluoroalkyl, wherein the alkyl and cycloalkyl groups are optionally substituted by halogen, -CN, C_1-C_6 alkoxy, -COOH, -CH_2CO_2H, -$C(O)CH_3$, -CO_2R_7, -$C(O)NH_2$, -$S(O)_2CH_3$, -OH, -NH_2, or -NO_2;

R_3 is: (a) hydrogen, halogen, C_1-C_8 alkyl, C_1-C_8 alkenyl, C_1-C_8 alkynyl, C_3-C_6 cycloalkyl, -CH_2-C_3-C_6 cycloalkyl, heteroaryl, or phenyl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, and phenyl groups are optionally substituted by from 1 to 3 groups selected from halogen, C_1-C_3 alkyl, C_1-C_3 haloalkyl, C_1-C_3 perfluoroalkyl, C_1-C_3 alkoxy, C_1-C_3 perfluoroalkoxy, C_1-C_3 alkylthio, C_1-C_3 perfluoroalkylthio, -$OCHF_2$, -CN, -COOH, -CH_2CO_2H, -$C(O)CH_3$, -CO_2R_7, -$C(O)NH_2$, -$S(O)_2CH_3$, -OH, -NH_2, or -NO_2;

or (b) the moiety X-R_6;

R_6 is C_1-C_8 alkyl, C_1-C_8 alkenyl, C_1-C_8 alkynyl, C_3-C_6 cycloalkyl, -CH_2-C_3-C_6 cycloalkyl, heteroaryl, phenyl, aryl-alkyl where the alkyl chain is C_1-C_8, CH_2CH_2-phenyl, or CH_2CH_2-napthyl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, phenyl, and napthyl groups are optionally substituted by from 1 to 3 groups selected from halogen, C_1-C_3 alkyl, C_1-C_3 perfluoroalkyl, -O-C_1-C_3 perfluoroalkyl, -S-C_1-C_3 perfluoroalkyl, C_1-C_3 alkoxy, -$OCHF_2$, -CN, -$C(O)CH_3$, -CO_2R_7, -$S(O)_2CH_3$, -OH, -NH_2, or -NO_2; and

R_7 is C_1-C_6 alkyl, C_3-C_6 cycloalkyl, -CH_2-C_3-C_6 cycloalkyl, or ~~C_4-C_8~~ aryl-alkyl <u>where the alkyl chain is</u> C_1-C_8.

or a pharmaceutically acceptable salt or ester form thereof.

2. (Previously presented) A compound of formula (II):



(II)

wherein:

R_4 is hydrogen, halogen, C_1-C_6 alkyl, C_1-C_3 haloalkyl, C_1-C_3 perfluoroalkyl, -O-C_1-C_3 perfluoroalkyl, -S-C_1-C_3 perfluoroalkyl, C_1-C_3 alkoxy, $-OCHF_2$, -CN, $-C(O)CH_3$, $-CO_2R_7$, $-S(O)_2CH_3$, -OH, $-NH_2$, or $-NO_2$;

R_5 is C_1-C_8 alkyl, C_1-C_3 perfluoroalkyl, $-CH_2$-C_3-C_6 cycloalkyl, $-CH_2$-heteroaryl, or aryl-alkyl where the alkyl chain is C_1-C_8, wherein the rings of the cycloalkyl, heteroaryl, and aryl groups are optionally substituted by from 1 to 5 groups selected from halogen, C_1-C_3 alkyl, C_1-C_3 perfluoroalkyl, -O-C_1-C_3 perfluoroalkyl, S-C_1-C_3 perfluoroalkyl, C_1-C_3 alkoxy, $-OCHF_2$, -CN, $-C(O)CH_3$, $-CO_2R_7$, $-S(O)_2CH_3$, -OH, $-NH_2$, or $-NO_2$;

R_2 is hydrogen, C_1-C_6 alkyl, or C_1-C_3 perfluoroalkyl, wherein the alkyl group is optionally substituted by halogen, -CN, C_1-C_6 alkoxy, -COOH, $-CH_2CO_2H$, $-C(O)CH_3$, $-CO_2R_7$, $-C(O)NH_2$, $-S(O)_2CH_3$, -OH, $-NH_2$, or $-NO_2$;

R_3 is hydrogen, halogen, C_1-C_8 alkyl, C_1-C_8 alkenyl, C_1-C_8 alkynyl, C_3-C_6 cycloalkyl, $-CH_2$-C_3-C_6 cycloalkyl, heteroaryl, or phenyl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, and phenyl groups are optionally substituted by from 1 to 3 groups selected from halogen, C_1-C_3 alkyl, C_1-C_3 perfluoroalkyl, -O-C_1-C_3 perfluoroalkyl, -S-C_1-C_3 perfluoroalkyl, C_1-C_3 alkoxy, $-OCHF_2$, -CN, $-C(O)CH_3$, $-CO_2R_7$, $-S(O)_2CH_3$, -OH, $-NH_2$, or $-NO_2$; and

R_7 is C_1-C_6 alkyl, C_3-C_6 cycloalkyl, -CH_2-C_3-C_6 cycloalkyl, or aryl-alkyl where the alkyl chain is C_1-C_8;

or a pharmaceutically acceptable salt or ester form thereof.

3. (Original) The compound of Claim 1 which is (1-{4-[(4-cyanobenzyl)oxy]phenyl}-*1H*-indol-3-yl)(oxo)acetic acid, or a pharmaceutically acceptable salt or ester form thereof.

4. (Original) The compound of Claim 1 which is {1-[4-(3-methoxy-benzyloxy)-phenyl]1*H*-indol-3-yl}-oxo-acetic acid, or a pharmaceutically acceptable salt or ester form thereof.

5. (Original) The compound of Claim 1 which is {1-[4-(3-chloro-benzyloxy)-phenyl]1*H*-indol-3-yl}-oxo-acetic acid, or a pharmaceutically acceptable salt or ester form thereof.

6. (Original) The compound of Claim 1 which is {1-[4-(4-cyanobenzyloxy)-phenyl]-5-fluoro-1*H*-indol-3-yl}-oxo-acetic acid, or a pharmaceutically acceptable salt or ester form thereof.

7. (Original) The compound of Claim 1 which is {1-[4-(3,5-dimethoxy-benzyloxy)-phenyl]-5-fluoro-1*H*-indol-3-yl}-oxo-acetic acid, or a pharmaceutically acceptable salt or ester form thereof.

8. (Original) The compound of Claim 1 which is {1-[4-(3-chloro-benzyloxy)-phenyl]-5-methyl-1*H*-indol-3-yl}-oxo-acetic acid, or a pharmaceutically acceptable salt or ester form thereof.

9. (Previously presented) The compound which is {1-[4-(4-*tert*-butyl-benzyloxy)-phenyl]-5-methyl-1*H*-indol-3-yl}-oxo-acetic acid, or a pharmaceutically acceptable salt or ester form thereof.

10. (Original) The compound of Claim 1 which is {1-[4-(2,4-dichlorobenzyloxy)-phenyl]-5-methyl-1*H*-indol-3-yl}-oxo-acetic acid, or a pharmaceutically acceptable salt or ester form thereof.

11. (Original) The compound of Claim 1 which is {5-Chloro-1-[3-(4-cyano-benzyloxy)-phenyl]1*H*-indol-3-yl}-oxo-acetic acid, or a pharmaceutically acceptable salt or ester form thereof.

12. (Original) The compound of Claim 1 which is {5-Chloro-1-[3-(3,5-dimethoxy benzyloxy)-phenyl]1*H*-indol-3-yl}-oxo-acetic acid, or a pharmaceutically acceptable salt or ester form thereof.

13. (Original) The compound of Claim 1 which is {1-[4-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzyloxy)-phenyl]1*H*-indol-3-yl}-oxo-acetic acid, or a pharmaceutically acceptable salt or ester form thereof.

14. (Previously presented) The compound which is {1-[4-(4-[1,2,3]thiadiazol-4-yl-benzyloxy)-phenyl]-1H-indol-3-yl}-oxo-acetic acid, or a pharmaceutically acceptable salt or ester form thereof.

15. (Original) The compound of Claim 1 which is {1-[4-(2,6-dichloro-pyridin-4-ylmethoxy)-phenyl]1*H*-indol-3-yl}-oxo-acetic acid, or a pharmaceutically acceptable salt or ester form thereof.

16. (Previously presented) The compound of Claim 1 which [1-(4-{[5-(ethoxycarbonyl)-2-furyl]methoxy}phenyl)-5-fluoro-1H-indol-3- yl](oxo)acetic acid, or a pharmaceutically acceptable salt or ester form thereof.

17. (Original) The compound of Claim 1 which is {1-[4-(2,6-dichloropyridin-4-ylmethoxy)-phenyl]-5-methyl-1*H*-indol-3-yl}-oxo-acetic acid, or a pharmaceutically acceptable salt or ester form thereof.

18. (Original) The compound of Claim 1 which is {5-Chloro-1-[3-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzyloxy)-phenyl]1*H*-indol-3-yl}-oxo-acetic acid, or a pharmaceutically acceptable salt or ester form thereof.

19. (Previously presented) The compound of Claim 1 which is [5-chloro-1-(3-{[5-(ethoxycarbonyl)-2-furyl]methoxy}phenyl)-1H-indol-3- yl](oxo)acetic acid, or a pharmaceutically acceptable salt or ester form thereof.

20. (Previously presented) The compound which is {5-Chloro-1-[3-(4-[1,2,3]thiadiazol-4-yl-benzyloxy)-phenyl]1*H*-indol-3-yl}-oxo-acetic acid, or a pharmaceutically acceptable salt or ester form thereof.

21. (Original) The compound of Claim 1 which is {5-Chloro-1-[3-(2,6-dichloro-pyridin-4-ylmethoxy)-phenyl]1*H*-indol-3-yl}-oxo-acetic acid, or a pharmaceutically acceptable salt or ester form thereof.

22. (Original) The compound of Claim 1 which is [1,5-bis-(4-trifluoromethoxy-phenyl)-1H-indol-3-yl]-oxo-acetic acid, or a pharmaceutically acceptable salt or ester form thereof.

23-33. (Canceled)

34. (Original) A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutical carrier.

35. (Original) A method for the treatment of thrombosis or fibrinolytic impairment in a mammal, the method comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of Claim 1.

36. (Original) A method of Claim 35 wherein the thrombosis or fibrinolytic impairment is associated with formation of atherosclerotic plaques, venous and arterial thrombosis, myocardial ischemia, atrial fibrillation, deep vein thrombosis, coagulation syndromes, pulmonary fibrosis, cerebral thrombosis, thromboembolic complications of surgery or peripheral arterial occlusion.

37. (Original) A method for the treatment of peripheral arterial disease in a mammal, comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of Claim 1.

38. (Original) A method for the treatment of stroke associated with or resulting from atrial fibrillation in a mammal, comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of Claim 1.

39. (Original) A method for the treatment of deep vein thrombosis in a mammal, comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of Claim 1.

40. (Original) A method for the treatment of myocardial ischemia in a mammal, comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of Claim 1.

41. (Original) A method for the treatment of a cardiovascular disease caused by noninsulin dependent diabetes mellitus in a mammal, comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of Claim 1.

42. (Original) A method for the treatment of the formation of atherosclerotic plaques in a mammal, comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of Claim 1.

43. (Original) A method for the treatment of chronic obstructive pulmonary disease in a mammal, comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of Claim 1.

44. (Original) A method for the treatment of renal fibrosis in a mammal, comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of Claim 1.

45. (Original) A method for the treatment of polycystic ovary syndrome in a mammal, comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of Claim 1.

46. (Original) A method for the treatment of Alzheimer's disease in a mammal, comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of Claim 1.

47. (Currently amended) A method for the treatment of breast ~~and~~ or ovarian cancer in a mammal, comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of Claim 1.

48. (New) A compound of claim 1
wherein:

R_5 is arylalkyl where the alkyl chain is C_1-C_8, wherein the aryl group is optionally substituted by from 1 to 5 groups selected from halogen, C_1-C_3 alkyl, C_1-C_3 haloalkyl, C_1-C_3 perfluoroalkyl, C_1-C_3 alkoxy, C_1-C_3 perfluoroalkoxy, C_1-C_3 alkylthio, C_1-C_3 perfluoroalkylthio, $-OCHF_2$, -CN, -COOH, $-CH_2CO_2H$, $-C(O)CH_3$, $-CO_2R_7$, $-C(O)NH_2$, $-S(O)_2CH_3$, -OH, $-NH_2$, or $-NO_2$;

or a pharmaceutically acceptable salt or ester form thereof.

49. (New) compound of claim 1
wherein:

R_5 is C_3-C_6 cycloalkyl, $-CH_2$-C_3-C_6 cycloalkyl, heteroaryl, $-CH_2$-heteroaryl, or arylalkyl where the alkyl chain is C_1-C_8, wherein the rings of the cycloalkyl, heteroaryl, and aryl groups are optionally substituted by from 1 to 5 groups selected from halogen, C_1-C_3 alkyl, C_1-C_3 haloalkyl, C_1-C_3 perfluoroalkyl, C_1-C_3 alkoxy, C_1-C_3 perfluoroalkoxy, C_1-C_3 alkylthio, C_1-C_3 perfluoroalkylthio, $-OCHF_2$, -CN, -COOH, $-CH_2CO_2H$, $-C(O)CH_3$, $-CO_2R_7$, $-C(O)NH_2$, $-S(O)_2CH_3$, -OH, $-NH_2$, or $-NO_2$;

or a pharmaceutically acceptable salt or ester form thereof.

50. (New) A compound of claim 2
wherein:

R_5 is aryl-alkyl where the alkyl chain is C_1-C_8, wherein the aryl group is optionally substituted by from 1 to 5 groups selected from halogen, C_1-C_3 alkyl, C_1-C_3 perfluoroalkyl,

-O-C_1-C_3 perfluoroalkyl, S-C_1-C_3 perfluoroalkyl, C_1-C_3 alkoxy, -$OCHF_2$, -CN, -$C(O)CH_3$, -CO_2R_7, -$S(O)_2CH_3$, -OH, -NH_2, or -NO_2;

or a pharmaceutically acceptable salt or ester form thereof.

52. (New) A compound of claim 2

wherein:

R_5 is -CH_2-C_3-C_6 cycloalkyl, -CH_2-heteroaryl, or aryl-alkyl where the alkyl chain is C_1-C_8, wherein the rings of the cycloalkyl, heteroaryl, and aryl groups are optionally substituted by from 1 to 5 groups selected from halogen, C_1-C_3 alkyl, C_1-C_3 perfluoroalkyl, -O-C_1-C_3 perfluoroalkyl, S-C_1-C_3 perfluoroalkyl, C_1-C_3 alkoxy, -$OCHF_2$, -CN, -$C(O)CH_3$, -CO_2R_7, -$S(O)_2CH_3$, -OH, -NH_2, or -NO_2;

or a pharmaceutically acceptable salt or ester form thereof.